Japanese pharma group Otsuka has agreed to acquire Transcend Therapeutics and its MDMA-based drug candidate for post-traumatic stress disorder (PTSD) and other psychiatric conditions for $700 million ...

Insilico Medicines has once again added to its roster of big pharma partners, signing a deal with Eli Lilly that includes a $115 million upfront payment. The agreement – which could be worth as much ...

In a phase 2 trial, an antiretroviral combination developed by Gilead Sciences and MSD suppressed HIV with a single weekly oral dose, raising the hope of a new treatment option for patients. The new ...

Toymaker Mattel has launched its latest addition to the Barbie range of dolls, the first with type 1 diabetes, which comes complete with a wearable continuous glucose monitor (CGM) and insulin pump.

Digital health company Noom has started offering lower doses of GLP-1 agonist semaglutide, the active ingredient in Novo Nordisk's weight-loss drug Wegovy, at a knock-down price. The 'microdose' ...

Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on procedural ...

Users of weight-loss and diabetes therapies based on GLP-1 agonists have been warned to be aware of a rare complication, pancreatitis, that can be severe. The UK medicines regulator, the MHRA, has ...

Moderna has accused the FDA of moving the goal posts and being inconsistent with earlier advice. The FDA has refused to accept Moderna's marketing application of an mRNA-based seasonal influenza ...

Roche's Genentech unit has started work on a $700 million manufacturing facility in North Carolina, part of a promised $50 billion investment in the US. The plant – its first on the East Coast of the ...

Novo Nordisk has moved quickly to file for approval of a new, higher-dose version of its obesity therapy Wegovy as it tries to fend off a growing challenge in the market from arch-rival Eli Lilly.

Jazz Pharmaceuticals has become the first drugmaker to get FDA approval for a treatment for diffuse midline glioma with H3 K27M mutations, a rare brain cancer mainly affecting young people. The ...

Otsuka has claimed FDA approval for its IgA nephropathy (IgAN) therapy Voyxact, joining an increasingly crowded market and beating rival Vera Therapeutics to the punch. Anti-APRIL antibody Voyxact ...